Calibr, A Division Of Scripps Research
Clinical trials sponsored by Calibr, A Division Of Scripps Research, explained in plain language.
-
Engineered immune cells join forces with biologic drug to attack advanced breast cancer
Disease control OngoingThis early-stage study tests a new two-part treatment for people with advanced breast cancer that has not responded to standard therapies. Participants receive a single infusion of their own engineered immune cells (CLBR001) followed by cycles of an antibody-based drug (ABBV-461)…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Promising autoimmune therapy trial pulled before it began
Disease control TerminatedThis study planned to test a new treatment for people with autoimmune diseases such as lupus, scleroderma, and myositis. The treatment combined a patient's own engineered immune cells with a targeted antibody drug. However, the trial was withdrawn before enrolling any participant…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
15-Year watch begins for gene therapy recipients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 40 people who have already received CLBR001, a gene therapy using a lentiviral vector. Researchers will monitor them for 15 years to check for any delayed side effects or safety concerns. The goal is to understand the long-term risks of this treatment, not to t…
Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 01, 2026 15:59 UTC